Modulation of Tau Pathology in Alzheimer’s Disease by Dietary Bioactive Compounds
International Journal of Molecular Sciences · 09.01.2024 · 25 (2) · 831
DOI: 10.3390/ijms25020831 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 09.01.2024. Verfasst von Huahua Shi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, Harbin Institute of Technology, Weihai 264209, China. Hauptthemen laut MEDLINE: Tauopathies, Biological Products. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 170 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shandong Provincial Natural Science Foundation, Research fund from Weihai Science and Technology Development Program..
Themen: Demenz
Abstract (Originalsprache)
Tau is a microtubule-associated protein essential for microtubule assembly and stability in neurons. The abnormal intracellular accumulation of tau aggregates is a major characteristic of brains from patients with Alzheimer’s disease (AD) and other tauopathies. In AD, the presence of neurofibrillary tangles (NFTs), which is composed of hyperphosphorylated tau protein, is positively correlated with the severity of the cognitive decline. Evidence suggests that the accumulation and aggregation of tau cause synaptic dysfunction and neuronal degeneration. Thus, the prevention of abnormal tau phosphorylation and elimination of tau aggregates have been proposed as therapeutic strategies for AD. However, currently tau-targeting therapies for AD and other tauopathies are limited. A number of dietary bioactive compounds have been found to modulate the posttranslational modifications of tau, including phosphorylation, small ubiquitin-like modifier (SUMO) mediated modification (SUMOylation) and acetylation, as well as inhibit tau aggregation and/or promote tau degradation. The advantages of using these dietary components over synthetic substances in AD prevention and intervention are their safety and accessibility. This review summarizes the mechanisms leading to tau pathology in AD and highlights the effects of bioactive compounds on the hyperphosphorylation, aggregation and clearance of tau protein. The potential of using these bioactive compounds for AD prevention and intervention is also discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bioengineering, Harbin Institute of Technology, Weihai 264209, China.
- School of Chemistry and Chemical Engineering, Harbin Institute of Technology, Harbin 150001, China.
ORCID-Profile: Yan Zhao
Förderung
- National Natural Science Foundation of China
- Shandong Provincial Natural Science Foundation
- Research fund from Weihai Science and Technology Development Program.
- Weihai Science and Technology Development Program
Zitieren
APA
Shi, H., & Zhao, Y. (2024). Modulation of Tau Pathology in Alzheimer’s Disease by Dietary Bioactive Compounds. International Journal of Molecular Sciences, 25(2), 831. https://doi.org/10.3390/ijms25020831
Vancouver
Shi H, Zhao Y. Modulation of Tau Pathology in Alzheimer’s Disease by Dietary Bioactive Compounds. International Journal of Molecular Sciences. 2024;25(2):831. doi:10.3390/ijms25020831
BibTeX
@article{Shi2024,
author = {Shi, Huahua and Zhao, Yan},
title = {Modulation of Tau Pathology in Alzheimer’s Disease by Dietary Bioactive Compounds},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {2},
pages = {831},
doi = {10.3390/ijms25020831}
}
EUVIMED